Emerging treatment options for type 2 diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus (T2DM) is rapidly increasing in prevalence and is a major public health problem. It is a progressive disease which commonly requires multiple pharmacotherapy. Current options for treatment may have undesirable side effects (particularly weight gain and hypoglycaemia) and contraindications, and little effect on disease progression. Incretin based therapy is one of several newer therapies to improve glycaemia and is available in two different forms, dipeptidyl peptidase‐4 (DPP‐4) inhibitors and glucagon‐like peptide‐1 (GLP‐1) agonists. Use of these agents results in a ‘glucose‐dependant’ increase in insulin secretion and glucagon suppression resulting in improved glycaemia with low incidence of hypoglycaemia. DPP‐4 inhibitors are oral drugs which are weight neutral, while GLP‐1 agonists are injected subcutaneously and help promote weight loss while improving glycaemia. GLP‐1 agonists have also been shown to increase beta cell mass in rat models. Bariatric surgery is another option for the obese patient with T2DM, with blood glucose normalizing in over half of the patients following surgery. Other therapies in development for the treatment of T2DM include sodium‐glucose transporter 2 (SGLT‐2) inhibitors, glucagon receptor antagonists, glucokinase activators and sirtuins. In this article, we will review the various existing and emerging treatment options for T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551
Pories, W. J., Swanson, M. S., MacDonald, K. G., Long, S. B., Morris, P. G., Brown, B. M., Barakat, H. A., deRamon, R. A., Israel, G., Dolezal, J. M., et al. (1995) · Annals of Surgery · doi:10.1097/00000658-199509000-00011 · Cited by 2,293
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Association of depression and diabetes complications: a meta-analysis
de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00015 · Cited by 1,799
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Cited by
Nicolucci, A., Kovacs Burns, K., Holt, R. I. G., Comaschi, M., Hermanns, N., Ishii, H., Kokoszka, A., Pouwer, F., Skovlund, S. E., Stuckey, H., et al. (2013) · Diabetic Medicine · doi:10.1111/dme.12245 · Cited by 739
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
Ferrannini, E., & Solini, A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.243 · Cited by 458
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Broedl, U. C., Woerle, H. J., & on behalf of the EMPA-REG MET Trial Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2105 · Cited by 400
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
“Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has been shown to improve glycemic control (13), delay gastric emptying, and induce weight loss in people with type 2 diabetes (14,15).”
BackgroundAmbery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Metadata
- Authors
- Piya, M. K., Tahrani, A. A., & Barnett, A. H.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-05-27
- Volume
- 70
- Issue
- 5
- Pages
- 631-644
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1931319935
- Cited by
- 72
- References
- 48
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging treatment options for type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1365-2125.2010.03711.x
- The paper
- Piya, M. K., Tahrani, A. A., & Barnett, A. H. (2010). Emerging treatment options for type 2 diabetes. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2010.03711.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.